Spironolactone
Product Images NDC 51655-636

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 51655-636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 636 26)

NDC number 51655-636-26 refers to Spironolactone Tablets, USP, containing 25mg per tablet. This prescription medication is available in a bottle containing 90 tablets, and it is limited to prescription use only. It is recommended to follow the package insert for dosage. The tablets should be stored at controlled room temperature and protected from direct light, and must be kept out of the reach of children. The repackager of the product is Northwind Pharmaceuticals, and the original manufacturer is listed as Zydus Pharmaceuticals (USA) Inc. The label includes the lot number and expiration date.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 01)

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)

This text appears to be a summary of a clinical trial investigating the efficacy of spironolactone versus a placebo. The trial included 822 individuals receiving the drug and 841 individuals receiving a placebo. A log-rank test was performed, and it resulted in a p-value of less than 0.001. It is not clear what the trial was investigating or what the time period (measured in months) on the x-axis represents.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)

This is a tabulated dataset showing various characteristics of the subjects in a clinical trial evaluating the effectiveness of spironolactone compared to placebo. The table includes information on age, sex, race, ejection fraction (LVEF), heart failure, NYHA (New York Heart Association) classification, diabetes, serum creatinine levels, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, beta-blocker use, and the number of subjects in each subgroup. There is also a comparison of the efficacy of spironolactone versus placebo in improving the outcome.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.